Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $270.35, but opened at $289.84. UCB shares last traded at $287.4875, with a volume of 424 shares traded.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the company. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a research note on Monday, February 16th. Wolfe Research assumed coverage on UCB in a research note on Monday, February 23rd. They set an “outperform” rating for the company. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy”.
View Our Latest Research Report on UCB
UCB Price Performance
UCB Company Profile
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.
See Also
- Five stocks we like better than UCB
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
